<DOC>
	<DOCNO>NCT03017430</DOCNO>
	<brief_summary>It single blind randomized symptom trigger study ass efficacy safety pregablin combine symptom trigger treatment opiate withdrawal syndrome vs. clonidne symptom trigger treatment opiate withdrawal syndrome .</brief_summary>
	<brief_title>Pregabalin Opiate Withdrawal Syndrome</brief_title>
	<detailed_description>Study design : Single-blind randomized symptom-regulated protocol active control . Eighty patient admit inpatient addiction treatment program randomly assign two group . The first group ( N=40 ) receive 600 mg day Pregabalin six day along symptomatic therapy divide basic treatment give patient ( Doxylamin 30 mg/day ) additional medication base patient ' need determine psychiatrist use Opioid Withdrawal Scale include Ketorolac , Loperamide , Metoclopramide , Nefazolin Phenazepam ( benzodiazepine ) . The second group ( N= 40 ) receive 600 microgram Clonidine day main treatment along basic symptomatic regimen . Opiate withdrawal severity , crave , sleep disturbance , anxiety depression , well general clinical impression side effect assess daily psychiatrist blind patient ' group assignment use internationally validate quantitative psychometric instrument .</detailed_description>
	<mesh_term>Substance Withdrawal Syndrome</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<mesh_term>Loperamide</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<mesh_term>Phenazepam</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<mesh_term>Antidiarrheals</mesh_term>
	<criteria>Opioid Use Disorders ; Opioid Withdrawal Syndrome Severe psychiatric somatic disorder , Substance Use Disorders ( except tobacco )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>